An update on the other Abl Tyrosine Kinase Inhibition Phase 2 trial - PROSEEK by Sun Pharma Advanced Research Company (SPARC)

[jeffreyn]

After almost 5 years, enrollment (N=506) is now complete!

"The trial launched in 2019 and is expected to run through 2024."

Note that the Study Record on the Clinical Trials website has yet to be updated with this latest information. It still gives a Recruitment Status of "Recruiting" and an Estimated Study Completion Date of "March 2024".

The trial has a 40 week treatment period, followed by an optional long-term extension study. The length of the extension study is not stated, but as the trial has an Actual Study Start Date of February 2019, some of the early volunteers could (possibly) have received the drug for quite a long time.

parkinsonsnewstoday.com/new...

classic.clinicaltrials.gov/...